Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | AS605240 | 1 | 72 | 3.2 | 4915.0 | 5429.5 | 1554.9 | 0.505 | 0.893 | 0.905 | 1.804 | BT549 AS605240 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.032 | 3662.3 | 5856.5 | 1443.3 | -1.49 | 0.585 | 0.625 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Buparlisib | 1 | 72 | 0.001 | 5907.8 | 6321.8 | 1443.3 | -3.0 | 0.937 | 0.935 | 2.131 | BT20 BKM120 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.0032 | 3719.8 | 5781.0 | 1443.3 | -2.49 | 0.605 | 0.643 | 2.002 | BT20 Everolimus 0 1 |
| BT-549 | AZD-6482 | 1 | 72 | 0.1 | 4942.3 | 5406.8 | 1554.9 | -1.0 | 0.903 | 0.914 | 1.798 | BT549 AZD6482 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.1 | 3647.3 | 5856.5 | 1443.3 | -1.0 | 0.582 | 0.623 | 2.021 | BT20 Rapamycin 0 1 |
| BT-549 | AZD-6482 | 1 | 72 | 1.0 | 4299.3 | 5406.8 | 1554.9 | 0.0 | 0.761 | 0.795 | 1.798 | BT549 AZD6482 0 1 72 |
| BT-549 | AZD8055 | 1 | 72 | 0.001 | 5177.5 | 5342.3 | 1554.9 | -3.0 | 0.965 | 0.969 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-549 | AZD-6482 | 1 | 72 | 3.2 | 3911.8 | 5406.8 | 1554.9 | 0.505 | 0.671 | 0.723 | 1.798 | BT549 AZD6482 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 0.32 | 3778.3 | 5856.5 | 1443.3 | -0.495 | 0.610 | 0.645 | 2.021 | BT20 Rapamycin 0 1 |
| BT-549 | AZD8055 | 1 | 72 | 0.32 | 1896.5 | 5342.3 | 1554.9 | -0.495 | 0.118 | 0.355 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-20 | Everolimus | 1 | 72 | 0.01 | 3784.5 | 5781.0 | 1443.3 | -2.0 | 0.619 | 0.655 | 2.002 | BT20 Everolimus 0 1 |
| BT-549 | AZD8055 | 1 | 72 | 0.032 | 3250.8 | 5342.3 | 1554.9 | -1.49 | 0.513 | 0.608 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 1.0 | 3619.3 | 5856.5 | 1443.3 | 0.0 | 0.576 | 0.618 | 2.021 | BT20 Rapamycin 0 1 |
| BT-549 | AZD8055 | 1 | 72 | 1.0 | 2083.3 | 5342.3 | 1554.9 | 0.0 | 0.179 | 0.390 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-549 | Dactolisib | 1 | 72 | 0.001 | 5005.5 | 5568.8 | 1554.9 | -3.0 | 0.887 | 0.899 | 1.840 | BT549 BEZ235 0 1 72 |
| BT-549 | AZD8055 | 1 | 72 | 3.2 | 2039.5 | 5342.3 | 1554.9 | 0.505 | 0.165 | 0.382 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-20 | Sirolimus | 1 | 72 | 3.2 | 3597.5 | 5856.5 | 1443.3 | 0.505 | 0.571 | 0.614 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Buparlisib | 1 | 72 | 0.0032 | 5963.5 | 6321.8 | 1443.3 | -2.49 | 0.946 | 0.943 | 2.131 | BT20 BKM120 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.032 | 3677.3 | 5781.0 | 1443.3 | -1.49 | 0.595 | 0.636 | 2.002 | BT20 Everolimus 0 1 |
| BT-549 | Buparlisib | 1 | 72 | 0.0032 | 5223.8 | 5555.8 | 1554.9 | -2.49 | 0.934 | 0.940 | 1.837 | BT549 BKM120 0 1 72 |
| BT-20 | TGX221 | 1 | 72 | 0.001 | 5503.5 | 5723.8 | 1443.3 | -3.0 | 0.961 | 0.962 | 1.988 | BT20 TGX221 0 1 |
| BT-549 | Dactolisib | 1 | 72 | 1.0 | 1630.8 | 5568.8 | 1554.9 | 0.0 | 0.026 | 0.293 | 1.840 | BT549 BEZ235 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.32 | 2081.3 | 4308.0 | 1295.5 | -0.495 | 0.315 | 0.483 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.1 | 3095.0 | 4308.0 | 1295.5 | -1.0 | 0.653 | 0.718 | 1.733 | HCC38 Trametinib 0 1 72 |